Cyclacel Group PLC Announces Cyclacel Designates Aurora Kinase Inhibitor As Its Third Development Candidate

Cyclacel Group plc ("Cyclacel"), the cell cycle-focused biopharmaceutical company, announced today that CYC116 an Aurora kinase inhibitor, has entered IND-directed preclinical development. CYC116 is a small molecule investigational drug which demonstrated anticancer activity after oral administration in both hematological and solid tumor models. The company plans to file an Investigational New Drug (IND) application for CYC116 with the United States Food and Drug Administration in 2006.

Back to news